A method of treating corneal opacities

 

(57) Abstract:

The invention relates to medicine, veterinary medicine. In the morning impose pyrogens. In the evening optional subkonyunktivalno enter solution of dexamethasone or prednisolone followed by radiation Subatlantic reflex zones within 5-7 minutes Method reduces the treatment time.

The invention relates to veterinary medicine and can be used in the treatment of corneal opacities animals.

It is known that the cornea in animals treated biogenic stimulants, such as the vitreous body, tohoto, aloe Vera extract, lidz, inhazinue their intramuscularly, or by instillation of hormones or drug solutions, resolving opacities, such as potassium iodide.

The disadvantage of these methods is their low efficiency as plain products, while instillation in the conjunctival SAC of the erosion medicines with tears. In addition, it should be noted that in some cases, the turbidity may not dissolve at all and stay in the same place that reduces visual acuity or completely deprives an animal of the ability to see (Famin K. A. Eye diseases of animals. - M.: Kolos, 1968, 272 S.).

ha laser radiation (Matveev L. C., Bardakhchieva L. C. Laser injuries of the eyes of small animals. - Veterinary medicine, 1994, 4, S. 50-51). However, in some cases, possible side effects, such as the development of pigment opacity and increased intraocular pressure, which is undesirable.

There is a method of treatment of corneal opacities by pyrogenal (UCLan L. J. Treatment pyrogenal scar opacities of the cornea. - The health of Kazakhstan, 1972, 10, S. 70-71, prototype), in which for the treatment of corneal opacities used intramuscular injections of pyrogenal in a dose of from 10 to 350 MTD. The disadvantage of this method is the long time during which the medical effect.

In connection with the foregoing in veterinary ophthalmology is a problem of treatment of corneal opacities of various etiologies (excluding pigment).

The task is to achieve a therapeutic effect in a shorter period of time.

The problem is solved in that in the treatment of corneal opacities by injection of pyrogenal subkonyunktivalno enter solution hormone (dexamethasone or prednisolone) and irradiated subtlety reflexogenic zone of the laser wavelength 0.87-0.97 mm, a power of 0.1 W, within 5-7 m is m - intramuscularly pyrogens in doses from 100 to 500 MTD. In the evening subkonyunktivalno injected with 0.5 - 2 ml (depending on the size of the animal) solution of the hormone (e.g., dexamethasone or prednisolone). Then after 5-7 minutes after the evening injection of irradiated animal subtlety reflexogenic zone laser with a wavelength of 0.87-0.97 μm, with a capacity of 0.1 W for 5-7 minutes.

The number of injections of each drug substance from 3 to 15, the number of exposures corresponds to the number of injections of one of the drugs. The treatment is carried out through the day.

Example 1.

The purebred dog, nicknamed Squirrel, age 3 months. Diagnosis: corneal Opacity resulting from blunt trauma of the eye. The age of turbidity averaged 12-15 days. Animal intramuscularly in the morning were injected with increasing doses of 100 to 500 MTD of pyrogens, and in the evening subkonyunktivalno was administered 0.5 ml dexamethasone and irradiated subtlety reflexogenic zone of the laser power of 0.1 W, a wavelength of 0.87-0.97 μm. Previously all animals was performed sensitivity tests to pyrogenal and hormones.

The number of exposures in this example is 4 (one day), the number of injections of the hormone and pyrogenal - 4 (one day).

Example 2.

Cat breeds Persian, named Zoe, age 3 years. Diagnosis: Diffuse clouding of the cornea, resulting from the incorrect treatment of corneal ulcers. The age of turbidity was 2 months. The treatment was performed the same as in the previous case, however, the number of injections pyrogenal and hormone in this example was 10, respectively, and the number of exposures was also equal to 10 (6 minutes a day).

The increase in time of exposure was not accelerated resorption of haze and reducing the time of exposure increased the duration of treatment.

The lower dose hormone reduced the effectiveness of treatment and increase it caused side effects, inherent to these drugs.

Example 3.

Dog breed Pekingese named Joffrey, age 4 years. Diagnosis: corneal Opacity resulting from the burn of the cornea alkali, age turbidity was 2 weeks. Animal were injected with doses from 100 to 500 MTD of pyrogens, and then subkonyunktivalno were administered 0.5 ml of the hormone and irradiated subtlety reflexogenic zone of the laser every other day for 7 minutes. The number of exposures and injection in this case there were 15 treatments of each species. Change the>/P>Treatment in all cases was carried out through the day. With this method of treatment recovery time was decreased by 1.5 times on average.

The outcome of the disease is the cure.

A method of treating corneal opacities, including injections pyrogenal, characterized in that pyrogenes impose morning dose of 100-500 MTD and additionally evening subconjuctival enter 0.5 to 2.0 ml of the hormone dexamethasone or prednisolone followed by radiation after 5-7 min Subatlantic reflexogenic zones of the laser wavelength of 0.87 to 0.97 μm, a power of 0.1 W, for 5-7 minutes

 

Same patents:
The invention relates to medicine and can be used to treat ischemic heart disease with diffuse nature of the lesion of the coronary arteries
The invention relates to medicine and can be used for the treatment of patients with multiple sclerosis
The invention relates to medicine and can be used in the treatment of chronic myofascial pain

The invention relates to medicine, namely to septic surgery
The invention relates to medicine, neurology
The invention relates to medicine and can be used in the treatment and secondary prevention of chronic bronchitis
The invention relates to medicine, dermatology

The invention relates to medicine and can be used for the treatment of chronic hypertrophic pharyngitis
The invention relates to medicine and can be used in the treatment of cicatricial strictures esophageal-intestinal anastomoses

The invention relates to the field of medicine, particularly surgery, traumatology, orthopedics and other fields, and can be recommended for the treatment of trauma and orthopedic and other pathologies
The invention relates to pharmaceutical industry

The invention relates to medicine and veterinary medicine and relates to pharmacological agents that have antimicrobial, wound healing and anti-inflammatory action

The invention relates to the field of pharmacology, and relates to pharmaceutical preparations for the treatment of gastritis, reflux esophagitis, duodenitis, dyspepsia and ulcers
The invention relates to medicine, namely to the pharmaceutical industry, producing homeopathic medicines therapeutic and prophylactic purposes for various diseases

The invention relates to medicine, in particular to immunology and Nephrology
The invention relates to medicine, namely to immunology, and concerns the increase of non-specific anti-infective resistanceat body children
The invention relates to the field of medicine and for the treatment of skin injuries, wounds, burns and ulcers

The invention relates to medicine and can be used to prevent formation amabokoboko nephropathy in children

The invention relates to medicine, in particular to andrology, and can be used to treat patients with impaired male reproductive function
Up!